Introduction
Conventional therapies for both common and uncommon malignancies include radiation, chemotherapy, and surgery, and they are frequently combined in a multidisciplinary approach. The conventional approach to these treatments is to interfere with the development and survival of tumor cells to specifically target and eradicate cancer cells. Unfortunately, this restricts the effectiveness of these therapies since malignancies frequently return due to acquired mutations and cancer stem cells. Furthermore, these treatments frequently have a wide range of negative side effects. These problems have refocused clinical and scientific attention on immunotherapies. The innate and adaptive immune systems are triggered by cancer, similarly to how they are by other medical conditions. The immune system participates in every facet of the cancer response, including removing cancerous cells, preserving the balance between immune and tumor cells, and promoting the development of tumor cells in an immunocompetent host microenvironment. As a result, it plays a critical role in suppressing and promoting cancers. The discovery of neoantigens and a greater understanding of the immune system have focused on identifying and developing methods to boost immune responses aimed at eliminating these cancer cells and reactivating anti-tumor responses with the aid of memory cells in the event of a relapse.
What Is Immunotherapy?
The immune system of the body is used in immunotherapy to identify and eliminate cancer cells. The immune system detects foreign intruders, including malignant cells, and gets rid of them. Immunotherapy may prolong the survival of cancer patients by improving the immune system's capacity to identify and destroy cancer cells. Researchers are developing novel immunotherapy drugs to target a greater variety of cancer types.
How Does Immunotherapy Work?
The immune system's regular job is to protect the body against viruses, allergies, and malignant cells. Specialized cells constantly patrol the body to prevent tumor growth, identifying and eliminating damaged or malignant cells. On the other hand, cancer cells constantly evolve to avoid immune responses. Immunotherapy works by strengthening the immune system in two ways: first, by improving its ability to identify and eradicate malignant cells; second, by inducing the generation of immune cells that fight cancer, which may more successfully target and destroy cancerous cells.
What Cancers Does Immunotherapy Treat?
Healthcare professionals frequently consider immunotherapy to be the first or primary treatment for metastatic cancer. It can be used with targeted therapy, chemotherapy, or other anti-cancer medications. Different types of immunotherapy are used to target different types of cancer, and they all use different immune system components.
What Are the Types of Immunotherapy?
Types of immunotherapy include:
-
Checkpoint inhibitors.
-
Adoptive cell therapy (T-cell transfer therapy).
-
Monoclonal antibodies.
-
Cancer vaccines.
-
Immune system modulators.
1. Checkpoint Inhibitors: Checkpoints are a powerful defense mechanism used by the immune system to stop excessive responses that might damage healthy cells. T lymphocytes are produced in the bone marrow and are essential for fighting cancer cells and defending against infections. Immune checkpoints function as traffic monitors for T-cell activation and deactivation by regulating signaling through interactions with T-cell surface proteins.
Immunotherapy in the form of checkpoint inhibitors breaks the link between checkpoint proteins and other proteins, obstructing the signaling that eventually causes T-cells to deactivate. Through this intervention, T-cells can continue their unhindered destruction of cancer cells.
Checkpoint inhibitors are frequently used by medical professionals to treat a variety of malignancies, especially those that are advanced, metastatic, incurable, or resistant to conventional forms of treatment. Combinations with targeted treatment or chemotherapy are common. Checkpoint inhibitors are being used to treat an increasing variety of cancers; these include bladder, cervical, esophageal, head and neck, hepatocellular carcinoma, high-risk triple-negative breast cancer, kidney, melanoma, mesothelioma, and non-small cell lung cancer. More cancers are anticipated to be added to this list as future research is conducted on these drugs.
2. Adoptive Cell Therapy: T-cell transfer treatment, a type of adoptive cell therapy, strengthens the immune system's capacity to combat cancer. To specifically destroy cancer cells, medical professionals grow immune cells in a lab and then reintroduce them into the patient's body. The two main strategies for transferring T cells are Chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte (TIL) treatment.
-
CAR T-Cell Therapy: Through receptor modification, CAR T-cell therapy makes T cells more potent cancer fighters. Similar to anti-virus software, these receptors make sure T-cells recognize and destroy invaders, even when malignant cells use antigen masks. CAR T-cell therapy is used to treat blood malignancies such as multiple myeloma, lymphoma, and leukemia; research on its possible use in brain and breast cancer is still underway.
-
TIL Treatment: TIL treatment involves strengthening TIL cells to function as surveillance troops within malignant tumors. Reintroducing enhanced TIL cells obtained from tumors and treated to promote growth allows for the efficient disruption and battle of signals that suppress the immune system. TIL therapy has not yet been recognized by the FDA as a routine cancer treatment, but research is being done to determine whether it can be effective against bile duct cancer, melanoma, and cervical squamous carcinoma.
3. Monoclonal Antibody Therapy: By using lab-created antibodies, monoclonal antibody treatment boosts the immune system's capacity to fight cancer cells. These antibodies can specifically target elements of cancerous cells, preventing aberrant proteins from being transmitted or making it easier to transfer medications, poisons, or radioactive material to destroy cancer cells. This sort of treatment is categorized as targeted therapy and targets the genes, proteins, or tumor development sites associated with cancer. Acute lymphoblastic, hairy cell, acute myeloid, chronic lymphocytic, bladder, breast (including triple-negative), colorectal, lymphomas (non-Hodgkin, cutaneous T-cell, B-cell), multiple myeloma, and non-small cell lung cancer are among the cancers that are treated by more than 60 FDA-approved monoclonal antibody medications.
4. Cancer Vaccines: Human papillomavirus (HPV) vaccinations offer protection against infections that are associated with malignancies such as anal, throat, and penile cancers. These vaccinations train the body to identify potential cancerous cells and combat them.
5. Immunomodulators: The body's immunological response to cancer is enhanced by immunomodulators such as cytokines (interferons and interleukins) and immunomodulatory medications (thalidomide, lenalidomide, pomalidomide, imiquimod). Cytokines control the immune system's reaction, indicating when an attack on malignant cells is necessary and organizing the attack. While interleukins trigger immune responses, interferons inhibit the development of cancer cells. Immunomodulatory medications are used to treat advanced myeloma and lymphoma types by preventing the development of new blood vessels, which slows the growth of tumors.
Conclusion:
Immunotherapy provides a potential new approach to treating uncommon cancers. It uses the body's immune system to target and destroy cancer cells. Despite continuing hurdles that include the need for individualized treatments and further study, immunotherapy has demonstrated considerable success in improving outcomes for people with uncommon tumors. Immunotherapeutic approaches are poised to play a major role in changing the landscape of treating rare tumors, providing affected individuals with renewed hope and the possibility of prolonged disease control and improved quality of life.
